...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of gynecological cancer: official journal of the International Gynecological Cancer Society >Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
【24h】

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.

机译：复发性卵巢癌可操作性预测评分的前瞻性验证研究：多中心小组研究DESKTOP II。 AGO Kommission OVAR，AGO研究组，NOGGO，AGO-奥地利和MITO的项目。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction in recurrent ovarian cancer. Resectability was assumed if 3 factors were present: (1) complete resection at first surgery, (2) good performance status, and (3) absence of ascites. The DESKTOP II trial was planned to verify this hypothesis prospectively in a multicenter setting. METHODS: Participating centers prospectively enrolled all consecutive patients with platinum-sensitive first or second relapse. The score was applied to all patients, but centers were free to decide on therapy. All further therapies were documented, and the outcome of patients was analyzed. A 75% complete resection rate in 110 prospectively classified patients had to be achieved to confirm a positive predictive value of 2 or higher of 3 with 95% probability. RESULTS: A total of 516 patients were screened within 19 months; of these, 261 patients (51%) were classified as score positive, and 129 patients with a positive score and first relapse were operated on. The rate of complete resection was 76%, thus confirming the validity of this score regarding positive prediction of complete resectability in 2 or more of 3 patients. Complication rates were moderate including second operations in 11% and perioperative mortality in 0.8%. CONCLUSIONS: This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer. It can aid in the selection of patients who might benefit from secondary cytoreductive surgery and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.
机译：目的：DESKTOP I试验提出了预测复发性卵巢癌完全细胞减少的评分。如果存在3个因素，则假定可切除性：（1）第一次手术时已完全切除，（2）良好的状态，以及（3）没有腹水。计划进行DESKTOP II试验以在多中心环境中前瞻性地验证该假设。方法：参与中心对所有连续的铂敏感的第一次或第二次复发患者进行了前瞻性研究。该分数适用于所有患者，但是各中心可以自由决定治疗方案。记录所有进一步的疗法，并分析患者的预后。必须对110名前瞻性分类的患者达到75％的完全切除率，才能以95％的概率确认2或更高的3的阳性预测值。结果：在19个月内共筛查516例患者。其中，有261例患者（占51％）被分类为阳性，对129例具有阳性和首次复发的患者进行了手术。完全切除的比率为76％，从而证实了该评分在3名患者中有2名或更多患者中完全可切除性阳性预测方面的有效性。并发症发生率中等，包括第二次手术（11％）和围手术期死亡率（0.8％）。结论：该评分是第一个积极预测复发性卵巢癌手术结果的前瞻性验证工具。它可以帮助选择可能受益于二次细胞减灭术的患者，并将参加最近开始的随机前瞻性DESKTOP III试验，该试验研究手术在复发性铂敏感性卵巢癌中的作用。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号